Drug Trial Radar · NCT06053814
NS-050/NCNP-03 in Boys With DMD (Meteor50)
Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Sep 18, 2024
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- NS Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Nippon Shinyaku Co., Ltd.
- First posted
- Sep 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.
Conditions
- Duchenne Muscular Dystrophy
Interventions
NS-050/NCNP-03Drug
NS-050/NCNP-03 solution for IV infusion.
PlaceboDrug
NS-050/NCNP-03 placebo-matching solution for IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Overall Summary of Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to Week 24
- Part 1: Area Under the Plasma Concentration Versus Time Curve (AUC) of NS-050/NCNP-03Time frame: Day 1 (1st dose) for each dose level
- Part 1: Amount of Drug Excreted in Urine of NS-050/NCNP-03Time frame: Day 1 (1st dose) for each dose level
- Part 2: Change from baseline in skeletal muscle dystrophin protein by immunoblot (Western blot)Time frame: Baseline, Week25
Locations
19 sites in 5 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California
Children's Hospital Colorado
Aurora, Colorado
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Alberta Children's Hospital
Calgary, Alberta, Canada
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
London Health Sciences Centre
London, Ontario, Canada
National Hospital Organization Nagara Medical Center
Nagara, Gifu, Japan
Hyogo Medical University Hospital
Nishinomiya, Hyōgo, Japan
Miyagi Children's Hospital
Sendai, Miyagi, Japan
NHO Osaka Toneyama Medical Center
Toyonaka, Osaka, Japan
National Center of Neurology and Psychiatry
Kodaira, Tokyo, Japan
Seoul National University Hospital
Seoul, South Korea
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea
Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye)
Istanbul University
Istanbul, Turkey (Türkiye)
Yeditepe University Kosuyolu Hospital
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.